

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

Interim Report First Quarter 2021

STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 31.03.2021. The report is attached to this release and is also available on <https://stenocare.com/investor-relations/>

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

“Despite the continued challenges caused by Covid-19, STENOCARE experienced positive development in sales and is confident that Q1 2021 laid a solid foundation for a good 2021 to realize important milestones in the STENOCARE 2.0 strategy”

(DKKK)	01.01.2021	01.01.2020	01.01.2020	01.01.2019
	31.03.2021	31.03.2020	31.12.2020	31.12.2019
	3 months	3 months	9 months	12 months
Total income *)	420	93	198	16,206
Net sales	420	93	198	4,942
Operating profit before depreciation (EBITDA)	-3,148	-2,626	-11,831	4,417
Net financial items	-48	-917	-1,648	-2,112
Investments in tangible assets	2,412	6,608	18,540	6,632
Result per share (DKK)	-0.25	-0.32	-1.12	0.19
Solidity (%)	93	38	93	43

Result per share: The result for the period divided by the average number of shares. Total number of shares as of March 31, 2021, amounted to 11,676,126 (8,942,762). Average number of shares for the first quarter 2021 was 11,676,126 (8,942,762).

Solidity: Equity divided by total capital.

*Total income incl. net sales and other income.

Highlights during the period

- In February 2021 STENOCARE announced the first THC-CBD oil products have been delivered to Sweden, and together with the first THC oil products that were delivered in December 2020 – there are two different products available for Swedish patients.

Join STENOCARE CEO, Thomas Skovlund Schnegelsberg, in a live interview about the Q1 Report and the state of the business. The interview is live on Wednesday May 12, at 17:00 and will be in Danish. Later it will have Swedish subtitles added. Please visit <https://www.facebook.com/stenocare> to access the live interview. It will also be recorded for later viewing.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on May 6, 2021.

STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company's premises in Jutland, Denmark.

www.stenocare.dk www.stenocare.com www.stenocare.se